[ Genebra – 5 de abril de 2006 ]
DNDi espera que o relatório da OMS (CIPIH, sigla em inglês), juntamente com a resolução proposta por Brasil e Quênia na Assembléia Mundial de Saúde, encoraje a OMS a adotar medidas concretas para solucionar o problema das doenças negligenciadas.
[ Ginebra, Segovia, Madrid – 6 de marzo de 2008 ]
La Agencia Española de Cooperación Internacional y Desarrollo (AECID) destina 5 millones de euros a la Iniciativa de Medicamentos para Enfermedades Olvidadas (DNDi por sus siglas en inglés), la cual lleva a cabo la investigación y el desarrollo de tratamientos esenciales para enfermedades como la Tripanosomiasis Africana, la Leishmaniasis, la enfermedad de Chagas o la malaria.
[ Geneva – May 15, 2009 ]
5-year, GBP 18 Million Grant Supports DNDi’s Proven Drug Development Model
[ Paris – 14 juin 2006 ]
L’AFD (Agence Française de Développement) et la Fondation DNDi (Drugs for Neglected Diseases initiative) concluent aujourd’hui à Paris une convention de partenariat visant à soutenir le projet de développement de deux nouveaux traitements contre le paludisme.
[ Geneva / New York – February 23, 2009 ]
Greater Governmental Leadership is needed to Foster Medical Innovation for Millions Suffering from Neglected Diseases.
[Français] [Español] [Português]
[ Madrid and Geneva – March 6, 2008 ]
Spain’s Agencia Española de Cooperación Internacional (AECI) today granted EUR 5.0 million to the Drugs for Neglected Diseases initiative (DNDi) for essential research and development (R&D) of drugs for neglected diseases such as human African trypanosomiasis, leishmaniasis, Chagas disease, and malaria.
New York Times [ January 8, 2008 ]
“Jump-Start on Slow Trek to Treatment for a Disease“
Click here to read the full article
[ Geneva, Switzerland – December 12, 2007 ]
The Drugs for Neglected Diseases initiative (DNDi) has received a USD 25.7 million grant from the Bill & Melinda Gates Foundation to research and develop new medicines to treat human African trypanosomiasis (HAT), also known as sleeping sickness, and visceral leishmaniasis (VL).
[ Geneva, Switzerland – November 5, 2007 ]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has granted Drugs for Neglected Diseases initiative (DNDi) USD 2.3 million to be disbursed over 3 years for research and development that focuses on developing a low-cost formulation of amphotericin B to treat visceral leishmaniasis.
[ Paris, Geneva – June 14, 2006 ]
AFD (Agence Française de Développement) and DNDi (Drugs for Neglected Diseases initiative) finalised a partnership agreement today to support the development of two new drugs for malaria.
Drug Discovery News [ April 2006 ]
“Turning neglect into action”
Click here to read the full article
[ Geneva – April 5, 2006 ]
DNDi welcomes the final report of the WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). The report clearly states that it is imperative for governments to set global health priorities and promote innovation to develop and deliver much-needed medicines, vaccines, and diagnostics adapted to the needs of the sick and neglected in developing countries.
[Geneva –March 9, 2005 ]
UK government commits £6.5 million to DNDi’s research for new medicines for neglected diseases
RealHealthNews interview with Bernard Pecoul regarding DFID funding of DNDi.
[ Geneva – November 11, 2004 ]
Two important conferences convene this month that will decide the future of patients suffering from neglected diseases in the poorer countries of the world: The Ministerial Summit on Health Research, November 16-20 in Mexico City, and the Dutch Government / WHO “Priority Medicines for the Citizens of Europe and the World” meeting, 18 November in The Hague.